Board of Directors

Biography

Gilbert Achermann (Born 1964, Swiss citizen) has served as Chair of the Board of Directors of Sonova Holding AG since June 2025. He has been a non‑executive member of the Board since 2024 and is Chair of the Technology and Innovation Committee.

Gilbert Achermann served as Chair of the Board of Directors of Straumann Group from 2010 to 2024. Prior to this, he held the roles of Chief Financial Officer and subsequently Chief Executive Officer at Straumann Group, where he spent more than 12 years and played a key role in the company’s development into a global leader in the dental industry. In 2020, he was elected to the Board of Directors of Ypsomed Group and became its Chair in 2022. In the same year, he joined the Board of Directors of Unilabs S.A. and was appointed Chair of the Board in 2023. Since 2019, Gilbert Achermann has been a member of the Foundation Board and Supervisory Board of IMD in Lausanne, Switzerland, and was elected Vice Chair in 2026. He has also been a member of the Management Board of Swiss Medtech since 2020 and has served as its Vice President since 2024. From 2012 to 2024, he was a member of the Board of Directors of Julius Baer Group.

Gilbert Achermann holds a degree in Business Administration from the University of Applied Sciences in St. Gallen, Switzerland, and an Executive MBA from IMD Lausanne, Switzerland.

Outside mandates

Listed companies:

• Chair of the Board of Directors of Ypsomed Group

Other mandates:

• Chair of the Board of Directors of Unilabs S.A.
• Member of the Board Greenteg AG
• Member of the Management Board and Vice President of the Swiss Medtech Association
• Supervisory Board of IMD – International Institute for Management Development in Lausanne

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meetings: 5 out of 5 meetings attended ¹⁾
• Additional calls of the Board of Directors: 1 out of 1 calls attended

Holdings as of 31.03.2025

• Shares: 9'771
• Restricted Shares²⁾: 501
   

Biography

Gregory Behar (Born 1969, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2021. He is a member of the Technology and Innovation Committee and the Nomination and Compensation Committee. 

Since January 2024, Gregory Behar has been Chief Executive Officer of Recipharm AB, a contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Prior to this, he served as Chief Executive Officer of Nestlé Health Science from 2014 until 31 December 2023 and became a member of the Nestlé Executive Board in 2017. From 2011 to 2014, he was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA).

Earlier in his career, he held various leadership positions at Boehringer Ingelheim GmbH (Germany), Novartis AG and Nestlé SA. Gregory Behar holds an MBA from INSEAD, France, a Master of Science in Mechanical Engineering and Manufacturing from EPFL Lausanne, Switzerland, and a Bachelor of Science in Mechanical Engineering from the University of California, Los Angeles, USA.

Outside mandates

Listed companies: 

• n.a.

Other mandates:

• CEO of Recipharm AB
• Member of the Board of Directors of Amazentis SA
• Member of the Board of Directors of New Biologix (mandate held at the direction of Recipharm AB as part of his role as its CEO and thus, shall not be considered as an additional outside mandate)

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meetings: 5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1 calls attended
• Audit Committee: 4 out of 4 meetings and 1 out of 1 calls attended

Holdings as per 31.03.2025

• Shares: 2,563
• Restricted Shares¹⁾: 2,238

Biography

Lynn Dorsey Bleil (Born 1963, US citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2016. She is a member of the Technology and Innovation Committee and the Audit Committee.

Lynn Dorsey Bleil retired as Senior Partner (Director) from McKinsey & Company in the United States in 2013, after more than 25 years advising senior management teams and boards of healthcare companies. Her work focused on corporate and business unit strategy, mergers and acquisitions, and public policy across the healthcare value chain. She has served on the boards of Auspex Pharmaceuticals until its acquisition by Teva in March 2015, of DST Systems until its acquisition by SS&C in April 2018, and of Stericycle Inc. until its acquisition by Waste Management in November 2024. Lynn Dorsey Bleil holds a Bachelor’s degree in Chemical Engineering from Princeton University, USA, and a Master of Business Administration from the Stanford University Graduate School of Business, USA. Lynn Dorsey Bleil will not stand for re‑election at the 2026 Annual General Meeting.

Outside mandates

Listed companies:

• Member of the Board of Directors of Alcon Inc.
• Member of the Board of Directors of Amicus Therapeutics, Inc.

Other mandates:

• Chair of the Intermountain Healthcare Wasatch Back Hospitals Community Board (a non-profit organization)

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meetings: 5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1calls attended
• Audit Committee: 4 out of 4 meetings and 1 out of 1calls attended

Holdings as per 31.03.2025

• Shares: 7,621
• Restricted Shares¹⁾: 2,969

Biography

Roland Diggelmann (Born 1967, Swiss citizen) has been a non-executive member of the Board of Directors since 2021 and serves as member and chair on the Nomination and Compensation Committee. 

From 2019 until March 31, 2022, he has been CEO of Smith & Nephew plc, a UK-based leading global medical technology company active in orthopedics, sports medicine, and advanced wound management. From 2008 to 2012 he was managing director for the Asia / Pacific region and from 2012 until 2018 CEO of Roche Diagnostics. He previously held senior management positions in sales and marketing as well as strategic planning at Zimmer Holdings and Sulzer Medica (later known as Centerpulse).

With more than 20 years of executive experience in the medical device industry across many parts of the world and as CEO, Roland Diggelmann provides valuable input to the implementation of Sonova’s strategy. 

Roland Diggelmann studied Business Administration at the University of Bern, Switzerland.

Outside mandates

Listed companies: 

• Chair of the Board of Directors of Mettler Toledo International Inc.

Other mandates:

• Member of the Board of Directors of Berlin Heals AG
• Member of the Board of Directors of HeartForce AG
• Member of the Board of Directors of Navignostics AG
• Member of the Board of Directors of Osler Diagnostics Ltd.

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meeting:  5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1 calls attended
• Nomination and Compensation Committee: 5 out of 5 meetings and 1 out of 1 calls attended

Holdings as per 31.03.2025

• Shares: 2,238
• Restricted Shares¹⁾: 2,238

Biography 

Laura Stoltenberg (Born 1973, US citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2025. She is a member of the Technology and Innovation Committee.

Laura Stoltenberg currently serves as President and Chief Executive Officer of Cryosa, a clinical‑stage medical device company developing a novel therapeutic solution for obstructive sleep apnea. Prior to her current role, she held various senior leadership positions at Halma plc, Medtronic and GE Healthcare, with responsibilities spanning global operations, business development and technology‑driven healthcare solutions. She brings extensive executive experience in the medical technology sector, including leadership in growth initiatives, mergers and acquisitions, and business development, as well as in operational improvement and cost management within regulated healthcare environments.

Laura Stoltenberg holds a Master of Business Administration from Columbia Business School, USA, and Bachelor’s degrees in Electrical Engineering and Management from Bucknell University, USA.

Outside mandates

Listed companies:

• n.a.

Other mandates:

• President and CEO of Cryosa

Biography 

Julie Tay (Born 1966, Singapore citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2022. She is a member of the Nomination and Compensation Committee.

From 2013 to 2022, Julie Tay served as Senior Vice President and Managing Director, Asia Pacific, at Align Technology, Inc., and was a member of the company’s global Executive Management Committee. Align Technology is a global medical device company specializing in digital orthodontics and restorative dentistry, including the Invisalign system, iTero intraoral scanners and exocad CAD/CAM software. In this role, she was responsible for the Asia Pacific region, overseeing commercial operations, market development and organizational leadership across multiple markets.
Prior to Align Technology, Julie Tay held various management positions at Bayer Healthcare, JohnsonDiversey and Johnson & Johnson Medical, with responsibilities across commercial, operational and regional leadership functions.

Julie Tay holds a Bachelor of Arts degree from the National University of Singapore and a Master of Business Administration in International Marketing from Curtin University of Technology, Australia.

External mandates

Listed companies: 

• Member of the Board of Directors of EBOS Group Ltd.

Other mandates:

• n.a.

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meeting: 5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1 calls attended
• Nomination and Compensation Committee: 5 out of 5 meetings and 1 out of 1 calls attended

Holdings as per 31.03.2025

• Shares:  1,759
• Restricted Shares¹⁾: 1,759

Biography

Ronald van der Vis (Born 1967, Dutch citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2009. He is a member of the Audit Committee and chaired the committee from 2019 to 2021.

From 2009 until November 2012, Ronald van der Vis served as Group Chief Executive Officer of Esprit Holdings Limited, a global fashion and lifestyle company listed on the Hong Kong Stock Exchange. He previously held senior management roles at GrandVision N.V. (formerly Pearle Europe), which he joined in 1998, and served as Group Chief Executive Officer from 2004 to 2009.

His experience includes executive leadership roles in consumer‑facing and retail businesses, as well as involvement in mergers and acquisitions and corporate finance through executive and private‑equity operating roles.

He graduated from Nyenrode Business University in the Netherlands and holds a Master’s degree in Business Administration from Alliance Manchester Business School, United Kingdom.

Outside mandates

Listed companies:

• n.a.

Other mandates:

• Operating Partner, Co-Investor and Industry Advisor
• Chair of the Supervisory Board of European Dental Group
• Chair of the Supervisory Board of Equipe Zorgbedrijven
• Chair of the Supervisory Board of United Veterinary Care
• Member of the Supervisory Board of HEMA BV

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meetings: 5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1 calls attended
• Audit Committee: 4 out of 4 meetings and 1 out of 1 calls attended

Holdings as per 31.03.2025

• Shares: 7,591
• Restricted Shares¹⁾: 2,969

Biography

Adrian Widmer (Born 1968, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2020. He is a member and Chair of the Audit Committee.

Since 2014, Adrian Widmer has served as Group Chief Financial Officer of Sika AG, a global specialty chemicals company headquartered in Switzerland. In this role, he is responsible for the Group’s finance, controlling and reporting functions. Prior to this, he was Head of Group Controlling and Mergers & Acquisitions at Sika from 2007 to 2014. Before joining Sika, he held various management positions at BASF, Degussa and Textron Inc., with responsibilities across finance and controlling, business development and general management. Adrian Widmer has more than 25 years of executive experience in finance, controlling, business development and M&A, including long‑standing service as Group Chief Financial Officer of a listed industrial company.

He holds a Master of Science degree in Business and Economics from the University of Zurich, Switzerland, and has completed the Advanced Management Program at INSEAD, Fontainebleau, France.

Outside mandates

Listed companies:

• Group CFO of Sika AG

Other mandates:

• n.a.

Meeting attendance during the financial year 2024/25

• Regular Board of Directors meetings: 5 out of 5 meetings attended
• Additional calls of the Board of Directors: 1 out of 1 calls attended
• Audit Committee: 4 out of 4 meetings and 1 out of 1 calls attended

Holdings as per 31.03.2025

• Shares: 2,969
• Restricted Shares¹⁾: 2,969